April at CN Bio: Organ-on-a-chip news
The pace is picking up, and not just because it’s spring! This month, we’re seeing serious momentum across the regulatory and research landscape toward what we’ve long championed - human-relevant science!
The FDA ’s updated guidance on animal testing and the The National Institutes of Health (NIH)’s new strategic plan to prioritize non-animal methods, both made headline news across the globe. They point toward a future where New Alternate Methodologies (#NAMs), like Organ-on-a-Chip (#OOC), play a central role in safer, faster, smarter and more cost-effective drug development.
Our collaboration with CRO Pharmaron represents another instrumental step in the right direction, as they begin to integrate PhysioMimix technology across their global R&D platform to validate and promote OOC for their customers.
If you're working in renal safety, you'd be pleased to learn that customers at Texas A&M University successfully adapted the PhysioMimix OOC for nephrotoxicity assay use. Their assay outperformed traditional models and other OOC solutions in validation tests.
Meanwhile, our webinar series continues. Scroll down for further details.
📣 FDA says NAMs like OOC will replace animal testing in 3-5 years for mAb and other drugs
The FDA announced their ambitious plans to phase out animal testing requirements for monoclonal antibodies and other drugs in favour of human-relevant methods, including OOC, in the next 3-5 years. This endorsement underscores the growing importance of NAMs in drug development and aligns with CN Bio's vision and mission.
📰 NIH to prioritize human-based tools, like OOC, over animal models
In a subsequent announcement yesterday, the The National Institutes of Health (NIH) has launched a new initiative to reduce use of animals in NIH-funded research in favour of NAMs. This reaffirms a transformative shift toward technologies, such as PhysioMimix OOC, which provide greater human relevance and clinical translatability to reduce reliance on animal models.
🤝 CN Bio and Pharmaron enter new partnership to validate, promote & develop OOC assays
Under the agreement, Pharmaron will validate PhysioMimix technology across our existing applications, integrate OOC technologies into their R&D platform and develop new applications to address unmet drug discovery/ development need for their large and growing global customer network.
💻Upcoming Webinar: Harnessing liver-on-a-chip models for drug safety
Join CN Bio 's Dr. Emily Richardson and Dr. Tomasz Kostrzewski, plus Dr. Rhiannon Hardwick from BMS on May 13th, or 14th.
Our webinar explores the latest Liver-on-a-chip/Liver MPS advancements from CN Bio and their real-world application in Pharma. Learn how to improve drug safety testing by identifying complex, species-specific toxicity risks earlier in the process. Plus Bristol Myers Squibb (BMS) share their insights on onboarding with OOC and the use of Liver MPS in drug discovery.
▶️Webinar on demand: Advancing oligo therapies with OOC
If you missed Dr. Oliver Culley during the live broadcast of our webinar - Advancing oligonucleotide therapies with Liver-on-a-chip, it is now available on demand.
Discover how Liver-on-a-chip enables you to delineate oligonucleotide distribution, uptake, safety and dosing to bridge the gap between preclinical studies and clinical success.
🔬TAMU study investigates OOC as a predictive tool for nephrotoxicity
Congratulations to customers at Texas A&M University (TAMU), who presented a study exploring MPS use as a predictive tool for nephrotoxicants at this year's SOT Annual Meeting.
Their poster explored the predictivity of four in vitro platforms and found that PhysioMimix OOC offered the highest overall accuracy.
See you again in a month. Until then, don't forget to follow us on LinkedIn and subscribe to our newsletter - What's New at CN Bio?
Until next time...
Content Marketing Manager
Accelerating bioscience ecosystem growth through robust industry-university partnerships
3moGreat to see the update! Will your team be at BIO in June?
Global BD Professional 🗺️ | Life Science Enthusiast & Bioprenuer 🧬 | Marketing & GTM Strategiest 🎯 | Sales & Leadership Coaching 🚀
4moexciting moment, we're all witnissing a paradigm shift of OOC replacing animal test in this new era
Lead Scientist | Organ-on-a-chip | microphysiological systems | NAMs
4moWhat an exciting month it’s been!! Looking forward to see what May brings!
Scientist, Strategist and Founder of Viveo - creative marketing for science and technology companies
4moThere's a lot of interest in non-animal models at the moment. The winners will be those companies that adopt these technologies in their drug development processes first.